• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
【24h】

Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.

机译：肿瘤坏死因子-α阻滞：风湿性疾病的一种新疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Overproduction of tumor necrosis factor-alpha (TNF) plays a key role in the pathogenesis of rheumatoid arthritis (RA) and other chronic inflammatory diseases. In RA, excessive production of TNF-alpha can drive synovial inflammation and proliferation as well as degradation of articular cartilage and bone. The importance of TNF-alpha in these mechanisms is supported by the results of clinical trials. In these studies, treatment with etanercept and infliximab, two recently approved TNF-alpha inhibitors, has been shown to significantly decrease the signs and symptoms of joint inflammation and slow the progression of radiological joint damage. Although TNF-alpha inhibitors have had acceptable toxicity in clinical trials, commercial use of these agents has produced growing concerns about the potential risk for opportunistic infections, most notably the reactivation of latent tuberculosis. The TNF-alpha inhibitors stand as a powerful example of the therapeutic potential of a targeted biological agent. Longer-term clinical experience with these cytokine antagonists will illuminate their optimal use in RA and other rheumatic diseases.
机译：肿瘤坏死因子-α（TNF）的过量生产在类风湿关节炎（RA）和其他慢性炎症性疾病的发病机理中起关键作用。在RA中，TNF-α的过量产生可以驱动滑膜炎症和增殖以及关节软骨和骨骼的降解。临床试验结果支持了TNF-α在这些机制中的重要性。在这些研究中，已证明最近批准的两种TNF-α抑制剂依那西普和英夫利昔单抗治疗可显着降低关节发炎的体征和症状，并减慢放射性关节损伤的进展。尽管TNF-α抑制剂在临床试验中具有可接受的毒性，但这些药物的商业使用引起了人们对机会性感染（尤其是潜伏性结核病再激活）潜在风险的日益关注。 TNF-α抑制剂是靶向生物制剂治疗潜力的有力例证。这些细胞因子拮抗剂的长期临床经验将阐明它们在RA和其他风湿性疾病中的最佳用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号